Leerink Swann began coverage on shares of Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) in a research report report published on Friday morning, MarketBeat.com reports. The brokerage issued a market perform rating and a $7.00 price objective on the biotechnology company’s stock.

Other research analysts have also recently issued research reports about the company. HC Wainwright restated a buy rating and issued a $10.00 price target on shares of Trillium Therapeutics in a research note on Thursday, December 14th. Zacks Investment Research cut Trillium Therapeutics from a buy rating to a hold rating and set a $8.75 price target for the company. in a research note on Saturday, January 20th. Finally, ValuEngine cut Trillium Therapeutics from a hold rating to a sell rating in a research note on Friday, December 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Trillium Therapeutics presently has a consensus rating of Hold and a consensus price target of $10.94.

How to Become a New Pot Stock Millionaire

Trillium Therapeutics stock opened at $7.05 on Friday. Trillium Therapeutics has a 12 month low of $4.15 and a 12 month high of $13.30. The firm has a market capitalization of $92.69, a price-to-earnings ratio of -1.99 and a beta of 1.83.

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last posted its quarterly earnings results on Friday, March 9th. The biotechnology company reported ($0.72) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.83) by $0.11. sell-side analysts anticipate that Trillium Therapeutics will post -2.29 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of TRIL. Virtu Financial LLC purchased a new position in shares of Trillium Therapeutics in the fourth quarter worth $144,000. Citadel Advisors LLC purchased a new position in shares of Trillium Therapeutics in the fourth quarter worth $180,000. Wells Fargo & Company MN raised its stake in shares of Trillium Therapeutics by 57.7% in the fourth quarter. Wells Fargo & Company MN now owns 26,100 shares of the biotechnology company’s stock worth $189,000 after purchasing an additional 9,550 shares during the last quarter. Deutsche Bank AG raised its stake in shares of Trillium Therapeutics by 1,860.0% in the fourth quarter. Deutsche Bank AG now owns 115,288 shares of the biotechnology company’s stock worth $835,000 after purchasing an additional 109,406 shares during the last quarter. Finally, Artal Group S.A. purchased a new position in shares of Trillium Therapeutics in the fourth quarter worth $1,088,000. Hedge funds and other institutional investors own 55.56% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.dailypolitical.com/2018/04/17/trillium-therapeutics-tril-coverage-initiated-by-analysts-at-leerink-swann.html.

About Trillium Therapeutics

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.